NCT03604068

Brief Summary

This clinical study is designed to assesses the benefit of adding pulsed shortwave therapy to the postoperative pain and recovery protocol following Cesarean section. Pulsed shortwave therapy is a safe adjunct pain therapy for acute and chronic pain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
250

participants targeted

Target at P75+ for not_applicable postoperative-pain

Timeline
Completed

Started Apr 2018

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2018

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 5, 2018

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 27, 2018

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2018

Completed
Last Updated

July 27, 2018

Status Verified

May 1, 2018

Enrollment Period

8 months

First QC Date

June 5, 2018

Last Update Submit

July 19, 2018

Conditions

Keywords

Caesarean section

Outcome Measures

Primary Outcomes (1)

  • Medication Use

    Quantify the use of analgesic medications during 7 days of postoperative recovery.

    Data collected daily for 7 Days

Secondary Outcomes (3)

  • Change in Visual Analogue Pain

    Data collected for 7 Days

  • Time to patient Patient Mobility

    2 Days

  • Would Closure at Day 7, Wound Complications

    7 Days

Study Arms (2)

Active Group

ACTIVE COMPARATOR

Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as an active RecoveryRx Pulsed Short Wave Therapy device.

Device: RecoveryRx

Control Group

SHAM COMPARATOR

Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as a sham RecoveryRx Pulsed Short Wave Therapy device.

Device: Sham RecoveryRx

Interventions

A pulsed shortwave therapy medical device

Also known as: pulsed shortwave therapy
Active Group

A sham pulsed shortwave therapy medical device

Also known as: Sham pulsed shortwave therapy
Control Group

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Voluntarily
  • Performed using spinal anesthesia
  • ASA I (Normal healthy patients) and II (Patients with mild systemic disease) (as defined by the American Society of Anesthesiologists Physical Status Classification system)
  • PARA 0000, 1, 2, 3 \[i.e. First, Second, or Third C-Section)
  • At term pregnancy (\>38 weeks)
  • BMI \<35
  • Age between 18 - 50 years

You may not qualify if:

  • Longitudinal surgical incision
  • Placental abnormalities noted
  • Time of extraction of the fetus \>10 min from cutaneous incision
  • Blood loss during surgery of \>800 ml

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Haykal hospital

Tripoli, Lebanon

RECRUITING

New Mazloum Hospital

Tripoli, Lebanon

RECRUITING

Related Publications (1)

  • Zimpel SA, Torloni MR, Porfirio GJ, Flumignan RL, da Silva EM. Complementary and alternative therapies for post-caesarean pain. Cochrane Database Syst Rev. 2020 Sep 1;9(9):CD011216. doi: 10.1002/14651858.CD011216.pub2.

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Moustafa Chaaban, MD

    Haykal hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mahmoud Maassarani, Ph.D

CONTACT

Omar Tabbouche, Pharma D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 5, 2018

First Posted

July 27, 2018

Study Start

April 1, 2018

Primary Completion

December 1, 2018

Study Completion

December 30, 2018

Last Updated

July 27, 2018

Record last verified: 2018-05

Locations